Education
About Us
Working with TipRanks
Follow Us
Getinge AB (GNGBY)
:GNGBY
Top Page
Getinge AB
(OTC:GNGBY)
67Neutral
Getinge AB (GNGBY) vs. S&P 500 (SPY)
Market Cap
$5.17B
Dividend Yield1.24%
Average Volume (3M)2.35K
Price to Earnings (P/E)33.9
Beta (1Y)0.75
Revenue Growth9.99%
EPS Growth-35.70%
CountryUS
Employees11,827
SectorHealthcare
Sector Strength64
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.56
Shares Outstanding254,152,370
10 Day Avg. Volume0
30 Day Avg. Volume2,345
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Getinge AB Business Overview & Revenue Model
Company DescriptionGetinge AB (GNGBY) is a global medical technology company based in Sweden that offers innovative healthcare solutions. The company operates in sectors such as acute care therapies, surgical workflows, and life sciences, providing products and services that enhance the quality and efficacy of healthcare delivery. Getinge's core products include medical devices, equipment for operating rooms, intensive care units, and sterile reprocessing, as well as solutions for infection control and contamination prevention in the life sciences sector.
How the Company Makes MoneyGetinge AB generates revenue through the sale of its diverse range of medical technology products and services. The company's key revenue streams include the sale of capital equipment such as ventilators, anesthesia machines, and extracorporeal life support systems, as well as consumables and service contracts for maintenance and technical support. Getinge maintains significant partnerships with hospitals, healthcare facilities, and research institutions worldwide, which contribute to its revenue through long-term contracts and repeat business. Additionally, the company invests in research and development to innovate and expand its product offerings, thereby enhancing its market competitiveness and revenue potential.
Getinge AB Financial Statement Overview
Summary
Getinge AB demonstrates solid financial performance with stable revenue growth and efficient cash flow generation. There are slight declines in profit margins and return on equity, but the company's leverage remains well-managed, and its equity position is strong. Attention should be given to improving profit margins and equity returns.Income Statement
The company's revenue has shown a steady growth trend over the years, with a revenue growth rate of 9.2% from 2023 to 2024. However, both gross profit margin and net profit margin have experienced slight declines, with the net profit margin dropping to 4.7% in 2024 from 7.6% in 2023. Despite this, the EBIT and EBITDA margins remain stable, indicating sound operational efficiency.72
Positive
Balance Sheet
The balance sheet reflects strong equity standing with a debt-to-equity ratio of 0.33 in 2024, suggesting reasonable leverage. The equity ratio is at 51.6%, indicating a solid proportion of assets financed by equity. However, the return on equity has decreased to 5% in 2024, signaling less efficient use of equity compared to previous years.68
Positive
Cash Flow
The cash flow metrics are robust, with a strong operating cash flow to net income ratio of 2.8 in 2024, reflecting efficient cash generation. The free cash flow has doubled since 2023, indicating strong cash management. However, the free cash flow to net income ratio of 2 suggests a need for cautious investment approaches.75
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 34.76B | 31.83B | 28.29B | 27.05B | 29.82B | Gross Profit |
| 16.15B | 14.49B | 13.41B | 13.58B | 14.72B | EBIT |
| 2.85B | 3.74B | 3.63B | 4.37B | 4.78B | EBITDA |
| 6.17B | 5.91B | 5.70B | 6.15B | 7.20B | Net Income Common Stockholders |
| 1.64B | 2.41B | 2.49B | 2.97B | 3.24B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.96B | 2.73B | 5.68B | 4.08B | 6.06B | Total Assets |
| 63.92B | 53.59B | 52.03B | 44.55B | 45.01B | Total Debt |
| 10.73B | 8.08B | 5.82B | 4.31B | 10.21B | Net Debt |
| 7.77B | 5.35B | 148.00M | 230.00M | 4.15B | Total Liabilities |
| 30.71B | 23.18B | 21.58B | 19.38B | 23.53B | Stockholders Equity |
| 33.01B | 30.17B | 30.04B | 24.75B | 21.02B |
| Cash Flow | Free Cash Flow | |||
| 3.27B | 1.60B | 2.23B | 5.63B | 6.15B | Operating Cash Flow |
| 4.58B | 2.96B | 3.37B | 6.56B | 7.20B | Investing Cash Flow |
| -4.55B | -6.54B | -1.47B | -1.33B | -1.99B | Financing Cash Flow |
| 504.00M | 511.00M | -500.00M | -7.24B | -297.00M |
Getinge AB Technical Analysis
Negative
19.02
Price Trends
20.62
Negative
18.78
Positive
19.06
Positive
Market Momentum
-0.34
Positive
42.60
Neutral
86.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNGBY, the sentiment is Negative. The current price of 19.02 is below the 20-day moving average (MA) of 20.39, below the 50-day MA of 20.62, and below the 200-day MA of 19.06, indicating a neutral trend. The MACD of -0.34 indicates Positive momentum. The RSI at 42.60 is Neutral, neither overbought nor oversold. The STOCH value of 86.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNGBY.
Getinge AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $21.89B | 47.24 | 9.61% | 1.02% | -0.17% | -17.34% | |
67 Neutral | $5.17B | 33.89 | 4.54% | 1.24% | 9.99% | -35.70% | |
67 Neutral | $25.93B | 46.43 | 27.63% | ― | 11.34% | 4.24% | |
65 Neutral | $40.65B | 28.33 | 17.17% | ― | -4.67% | 6.23% | |
65 Neutral | $19.28B | 21.98 | 7.24% | 0.98% | 3.84% | -9.29% | |
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
49 Neutral | $22.40B | ― | -7.10% | ― | -0.76% | -55.03% |
* Healthcare Sector Average
Performance Comparison
GNGBY
Getinge AB
19.02
-1.98
-9.43%
DXCM
Dexcom
66.86
-71.15
-51.55%
EW
Edwards Lifesciences
70.46
-17.55
-19.94%
PHG
Koninklijke Philips
24.46
4.47
22.36%
STE
Steris
223.87
24.31
12.18%
ZBH
Zimmer Biomet Holdings
99.45
-19.25
-16.22%
Getinge AB Earnings Call Summary
Earnings Call Date: Apr 22, 2025 | % Change Since: -6.44% | Next Earnings Date: Jul 18, 2025
Earnings Call Sentiment Positive
The earnings call reflects a generally positive outlook with strong growth in order intake and sales, improved margins, and successful product launches. However, challenges such as currency headwinds, Life Science segment issues, and geopolitical uncertainties due to tariffs are notable concerns.Highlights
Strong Order Intake and Sales Growth
Order intake grew by 7.1% with 2.9% organic growth, and net sales increased by 10.7% with 6.2% organic growth. This growth was largely driven by Acute Care Therapies and strong performance in the Americas.
Improved Margins and Financial Stability
Adjusted gross and EBITDA margins improved by about 1 percentage point, with financial leverage remaining stable despite increased net debt from acquisitions.
Sustainability Efforts Showing Results
Positive trends in sustainability KPIs, including a reduction in the CO2 footprint and improved product quality metrics.
Successful Product Launches
The KidneyVault product launched successfully with positive feedback, and EU MDR approval was obtained for the majority of products, aiding expansion outside the U.S.
Recurring Revenue and High-Margin Products
Recurring revenue now makes up 65% of sales, with high-margin products accounting for about two-thirds of revenue.
Strategic Acquisitions Support Growth
Recent acquisitions are expected to contribute an additional 2% growth in 2025.
Lowlights
Currency Headwinds Impacting Margins
Currency fluctuations negatively impacted EBITDA margin by 1.1 percentage points in the quarter.
Life Science Segment Challenges
Life Science order intake was significantly down due to weak orders in the Bio-Processing subsegment.
Free Cash Flow Decline
Free cash flow decreased to SEK 0.2 billion, impacted by volume-driven inventory increases and unfavorable timing of accounts receivables.
Tariff and Geopolitical Uncertainty
Increased trade barriers and higher tariffs present challenges, with potential financial impacts still uncertain.
Company Guidance
In the Getinge Q1 2025 call, the company presented a strong performance with key metrics highlighting a 7.1% increase in order intake and a 10.7% rise in net sales, with 6.2% coming from organic growth. The adjusted gross and EBITDA margins improved by approximately 1 percentage point, primarily due to volume leverage, acquisitions, and favorable pricing. The company reported an adjusted gross profit of SEK 4.337 billion, and an adjusted EBITDA margin that increased to 12.1%. Despite currency headwinds, Getinge maintained solid financial leverage with net debt at SEK 9.7 billion and a leverage ratio of 1.4x adjusted EBITDA, below their internal threshold. They also highlighted a decrease in their CO2 footprint, positive trends in quality KPIs, and the successful integration and growth of recent acquisitions like Paragonix. The outlook for 2025 remains unchanged, with expected organic net sales growth between 2% to 5%.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.